หุ้นปันผลสูงในกลุ่มการแพทย์สามตัวที่น่าถือครอง

Novo Nordisk remains a leader in diabetes and weight loss markets with advancing candidates and diversification into rare blood diseases.

Pfizer offers a high forward dividend yield of 7.1% and is expected to benefit from products like Padcev and Abrysvo, along with a promising pipeline.

Sanofi is driven by strong Dupixent performance and pipeline prospects like frexalimab with potential peak sales over $1 billion.